IPSEN
Dysport
In this clinical study, we are looking at the impact Dysport has on chronic and episodic migraines. The goal is to see if this Botulinum toxin injection reduces the number of days with migraines.
Eligibility: For both the chronic and episodic migraine studies, eligible individuals began having migraines before turning 50 years old, and is at least 18 years old.
Status: RECRUITING
LUNDBECK
Lu AG09222
This research explores the potential Lu AG09222 has to reduce migraine days more effectively than a placebo. Lu AG09222 is a anti-PACAP antibody that will inhibit PACAP.
Eligibility: Individuals who have not found relief with 2-4 other treatments, began having migraines before they turned 50 years old, and are between 18 and 65 years old.
Status: RECRUITING
Allergan
UbreIvy
UbreIvy is an oral medication made for immediate treatment of migraines.
Status: Completed
FDA Approved
PROMISE
Eptinezumab
Eptinezumab (ALD403) is a CGRP antagonist for the prophylaxis of frequent episodic migraines.
Status: Completed
FDA Approved
TRIUMPH
Emgality
Emgality (galcanezumab) is a preventive treatment for migraines.
Status: Completed
FDA Approved